KRAS and non-small cell lung carcinoma: Similarly, trametinib, another MEK inhibitor, showed a similar PFS and response rate in patients with previously treated KRAS-mutant NSCLC, randomized to receive the MEK inhibitor or chemotherapy with docetaxel in a phase II trial [38].